Harmony Biosciences Holdings (HRMY) FCF Margin (2020 - 2026)
Harmony Biosciences Holdings recorded quarterly FCF Margin of 12.89% in Q1 2026, down 75.07% quarter-over-quarter from 51.7% in Q4 2025, and down 544.0% year-over-year from 2.9% in Q1 2025.
Harmony Biosciences Holdings' FCF Margin history runs 7 years deep, the most recent figure standing at 12.89% for Q1 2026.
- In Q1 2026, FCF Margin fell 544.0% year-over-year to 12.89%; the TTM figure through Mar 2026 stood at 38.01% (up 829.0% YoY), while the FY2025 annual figure was 40.06%, up 946.0% from the prior year.
- FCF Margin came in at 12.89% for Q1 2026 at Harmony Biosciences Holdings, down from 51.7% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 51.7% in Q4 2025 to a low of 12.89% in Q1 2026.
- A 5-year average of 33.45% and a median of 35.73% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin plunged 2036 bps in 2022 and soared 2467 bps in 2023, its largest moves.
- Harmony Biosciences Holdings' FCF Margin stood at 20.79% in 2022, then surged by 119 bps to 45.46% in 2023, then fell by 18 bps to 37.29% in 2024, then soared by 39 bps to 51.7% in 2025, then slumped by 75 bps to 12.89% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 12.89%, 51.7%, and 45.38% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | Harmony Biosciences Holdings | 1.83 Bn | 1.19 Bn | 170.88 Mn | 12.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.89% |
| Dec 31, 2025 | 51.70% |
| Sep 30, 2025 | 45.38% |
| Jun 30, 2025 | 39.56% |
| Mar 31, 2025 | 18.33% |
| Dec 31, 2024 | 37.29% |
| Sep 30, 2024 | 37.89% |
| Jun 30, 2024 | 24.29% |
| Mar 31, 2024 | 20.14% |
| Dec 31, 2023 | 45.46% |
| Sep 30, 2023 | 39.37% |
| Jun 30, 2023 | 27.61% |
| Mar 31, 2023 | 35.73% |
| Dec 31, 2022 | 20.79% |
| Sep 30, 2022 | 47.03% |
| Jun 30, 2022 | 31.48% |
| Mar 31, 2022 | 33.77% |
| Dec 31, 2021 | 41.15% |
| Sep 30, 2021 | 37.57% |
| Jun 30, 2021 | 24.21% |
| Mar 31, 2021 | 20.99% |
| Dec 31, 2020 | 17.85% |
| Sep 30, 2020 | 19.38% |
| Jun 30, 2020 | 12.71% |
| Mar 31, 2020 | -134.59% |